Largest False Claims Act Cases by Year: The Civil Amount Behind the Headline

The largest False Claims Act cases by year include GlaxoSmithKline’s drug settlement, Wells Fargo’s mortgage settlement, and the prescription drug judgments against Janssen and Omnicare. Their stories reach into sales departments, loan underwriting, prescription records, and government contract pricing.

These selected civil resolutions span 2000 through 2025. Civil settlements, court judgments, and bankruptcy claims appear separately.

Civil Settlements by Announcement Year

Teva and Raytheon settled in October 2024, after the Justice Department’s fiscal-year cutoff. Their settlements appear in its fiscal 2025 report.

HCA’s entries are separate agreements in separate years. GlaxoSmithKline’s manufacturing resolution also stands apart from its later promotion and rebate settlement. A single corporate headline can hide several distinct civil cases.

What Produced Those Settlement Amounts?

The alleged practices behind these settlements concern the inputs that determine payment: hospital charges, drug prices, loan eligibility, and contract costs. Those are familiar working records to the people who prepare or review them.

In HCA’s cases, the government alleged upcoding, unnecessary laboratory tests, improper home-health billing, false cost reports, and kickbacks. Tenet’s case focused heavily on a different reimbursement mechanism. The government alleged that Tenet raised charges faster than its costs increased, generating excessive Medicare outlier payments. We see the absurdity in that allegation: charging more became a reason for Medicare to pay more.

The pharmaceutical cases show several routes to the public bill. The government alleged that Pfizer’s promotion and kickbacks caused claims for noncovered uses. GlaxoSmithKline’s later settlement covered promotion, safety representations, and Medicaid rebate underpayments. A sales message, a payment to a prescriber, and the price reported to Medicaid reach the government through different records.

For Wells Fargo, the government alleged that the bank certified ineligible loans for government mortgage insurance and failed to report loan defects. At Booz Allen Hamilton, the allegations concerned commercial and international costs billed to government contracts. Both cases turn on which expenses or risks the government was asked to carry. An underwriter and a contract accountant would recognize very different documents behind that question.

Conditional Settlements and Bankruptcy Claims

Some civil settlements let a company satisfy part of its obligation through loan modifications. Others establish a government claim in bankruptcy.

Bank of America’s February 9, 2012 agreement required a $500 million immediate government payment and $500 million more owed later. Qualifying loan modifications could satisfy the later obligation, with the unused balance payable to the government. That agreement addressed allegations of reckless mortgage underwriting, inflated appraisals, and mortgage-modification eligibility practices. It was a separate resolution from the bank’s later entry in the table.

Purdue Pharma’s civil resolution, announced October 21, 2020, gave the government a $2.8 billion claim in bankruptcy, without collateral securing it. The Justice Department’s fiscal 2021 account included it in that form. The civil allegations concerned opioid promotion and kickbacks involving speakers, electronic health records, and pharmacies.

Endo’s February 29, 2024 civil resolution likewise appears in the fiscal 2024 report as a $475.6 million government claim in bankruptcy, also without collateral.

The Large Prescription Drug Judgments in 2025

The major prescription drug results in 2025 included court decisions after trial. Trial damages and judgments describe a different outcome from an agreement to settle.

The Justice Department’s annual fact sheet reported a $1.6 billion trial result against Janssen Products over claims induced by false and misleading statements about Prezista and Intelence. The court’s monetary decision included tripled damages and penalties for individual claims. The whistleblowers pursued that case.

Their complaint gives the sales practice a recognizable detail:

We see a sales pitch extending to the questions from the audience. For someone who worked on those programs, the invitation, the presentation, and the instructions behind it could tell much more than the event’s educational label.

In the Omnicare case, a jury found that Omnicare and CVS billed Medicare, Medicaid, and TRICARE for more than three million false claims involving drugs dispensed without valid prescriptions. The court entered a $948.8 million judgment in August 2025. The government pursued that case, unlike the whistleblower-run Janssen case.

The separate CVS Caremark case concerned inflated generic-drug prices reported by Medicare Part D plans. Following a trial before a judge, the August 19, 2025 judgment ordered $289,873,500 against the Caremark companies. Dispensing records in one case, reported drug prices in another. The pharmacy label covers both, but the proof comes from different parts of the business.

The Biggest Fiscal Totals Measure Many Cases

Fiscal 2025 produced the highest annual total reported by the Justice Department. The figures below are national settlements and judgments across many matters, not the amounts of individual cases.

The department’s statistical tables released January 16, 2026 give these major fiscal-year totals:

The full series runs from fiscal 1987 through fiscal 2025. The Congressional Research Service’s Qui Tam: The False Claims Act and Related Federal Statutes, published in 2009, explains how the 1986 amendments strengthened whistleblower participation in response to extensive fraud against the United States. The long series captures the enforcement that followed. The individual cases show the practices it reached.

Healthcare accounts for much of the recent money. For fiscal 2025, the department’s Health and Human Services category reported $5,721,536,531. Defense accounted for 633,927,500 dollars and other agencies for 532,632,235 dollars.

The same year’s cases reached beyond health care billing. The government alleged false defense-contract pricing at Raytheon, ignored cybersecurity findings at Health Net Federal Services, and aluminum extrusions packaged as sham furniture kits at Grosfillex. The annual fact sheet also includes pandemic-relief settlements and judgments. The public money moves through contracts and imports as well as medical claims.

What These Cases Mean for a Whistleblower

Whistleblowers can bring the inside account that connects a business practice to government payments. Biogen’s settlement resolved a whistleblower’s allegations that speaker, training, and consulting payments induced prescriptions. The whistleblower continued after the government declined to take over the case.

That distinction also appears in the national figures. Fiscal 2025 included $3,051,734,829 from qui tam cases the government joined or otherwise pursued and $2,288,271,506 from cases it declined. The government’s decision to join is one part of the case’s story.

In Pfizer’s settlement, six whistleblowers were to receive more than $102 million from the federal recovery.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with you to establish the connection between the claims, the payment, and what the company knew. A prescription record, a loan review, or a pricing instruction can give us that starting point.

The Practice Behind the Number

If these cases resemble the billing, sales, lending, or contracting practices you know, speak to one of our whistleblower experts about building your strongest False Claims Act case. We assess the payment trail with you, build the case with False Claims Act whistleblower lawyers who know your industry, and stay beside you through the outcome.